Lobulär cancer grad 2
Metastatic breast cancer also called stage IV or advanced breast cancer is breast cancer that has spread beyond the breast and nearby lymph nodes to other parts of the body.
Invasive Lobular Cancer (ILC)
CDHI inherited gene mutations increase the risk of breast cancer [ ]. Compared to invasive ductal cancer, invasive lobular cancer ILC is more likely to be [ , ]:. Learn more about breast anatomy. Learn about treatment for metastatic breast cancer. In the first 5 years after diagnosis, hormone receptor-positive breast cancers such as most ILC tend to have a lower risk of breast cancer recurrence than hormone receptor-negative breast cancers such as some IDC [ 12 ].
Hormone receptor-positive breast cancers can recur more than 10 years after diagnosis, while such late recurrences are rare for hormone receptor-negative cancers [ 12, ]. For example, hormone receptor-positive breast cancers can be treated with hormone therapies. Invasive lobular cancer ILC is the second most common type of invasive breast cancer invasive ductal cancer IDC is the most common [ ]. Treatment is based on breast cancer stage and other factors, such as hormone receptor status and HER2 status.
While invasive lobular cancer ILC can metastasize to these sites, it can also spread to sites not common with other breast cancers. Because ILC tumors grow in this way, there may not be a mass lump present. Learn more about Oncotype DX. The hormone receptor status of breast cancer is related recurrence a return of breast cancer and survival. Learn more about risk factors for breast cancer. Some findings show chemotherapy in addition to hormone therapy may not benefit all people with hormone receptor-positive, HER2-negative ILC [ ].
Read our fact sheet on invasive lobular breast cancer. This can make ILC harder to find on a mammogram than some other breast cancers. Invasive lobular cancer or infiltrating lobular carcinoma ILC is invasive breast cancer that begins in the lobules of the breast. Watch Susan G. Risk factors for invasive lobular cancer ILC are the same as those for other breast cancers. Oncotype DX ® is a test of tumor tissue that can help determine the benefit of adding chemotherapy to treatment for some hormone receptor-positive, HER2-negative early breast cancers.
For example, ILC sometimes may metastasize to the ovaries or the gastrointestinal tract including the stomach, colon and rectum [ ]. Hormone receptor-positive breast cancers have different patterns of recurrence and survival than hormone receptor-negative breast cancers do. However, a couple of factors may be related more often to ILC than other breast cancers. These and other factors guide treatment. Learn more about factors that guide breast cancer treatment.
Treatment for breast cancer is not based on whether the cancer is ILC, invasive ductal cancer or other tumor type.
Invasive Lobular Breast Cancer
Learn about treatment for early breast cancer. Find images and information about the warning signs of breast cancer. Learn more about breast cancer survival rates. While invasive lobular cancer ILC is usually hormone receptor-positive, invasive ductal cancer IDC can be hormone receptor-positive or hormone receptor-negative [ , ]. The most common sites of breast cancer metastasis are the bones, lungs, liver and brain.
Similarly, women with ILC tend to have better survival in the first years after diagnosis than women with IDC [ ]. This may explain some of the difference in longer-term breast cancer survival between women with ILC and women with IDC. As with all breast cancers, the most important factors related to survival for ILC are cancer stage and tumor grade. Treatment for invasive lobular cancer ILC is planned in the same way as treatment is planned for all breast cancers.
With ILC, the cancer cells in the lobules invade nearby breast tissue and may travel from the breast to other parts of the body. beneath a microscope, invasive lobular cancer ILC cells most often appear in a single en samling dokument eller en elektronisk lagring av data order. Learn more about the risk of breast cancer recurrence. Learn more about types of breast tumors. The lobules are small, round sacs in the breast that tillverka milk for breastfeeding.
It can help identify some people with hormone receptor-positive, HER2-negative ILC who may get a survival benefit from chemotherapy in addition to hormone therapy [ ]. So, in the first 5 years after diagnosis, women with hormone receptor-positive cancers tend to have better breast cancer survival than women with hormone receptor-negative cancers [ 12, ].